The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)
Launched by UNIVERSITY OF MICHIGAN · Apr 18, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The BioHOBIT trial is researching how certain biological markers in the blood can help doctors understand and treat severe traumatic brain injuries (TBI) more effectively. Currently, there aren’t any effective treatments for severe TBI, and doctors mostly rely on physical examinations, which can be challenging because patients are often unconscious or sedated. This study aims to test specific blood markers—like GFAP, NfL, and hsCRP—to see if they can predict how well patients respond to a treatment called hyperbaric oxygen therapy (HBOT). By identifying these markers, the researchers hope to improve treatment plans and make future clinical trials more efficient.
To be eligible for this study, participants must already be enrolled in the ongoing HOBIT trial, which explores the best doses of HBOT for TBI patients. People with severe anemia or those from whom blood samples cannot be taken will not be included. If you choose to participate, you can expect to provide blood samples and contribute to important research that could one day help other patients with severe TBI. This trial is currently recruiting participants of all genders aged between 18 to 74 years old.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Enrolled in HOBIT (this is an ancillary study to the HOBIT Trial)
- Exclusion Criteria:
- • Profoundly anemic (subjects who are profoundly anemic require blood transfusion)
- • Blood samples cannot be obtained
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Palm Beach, Florida, United States
Minneapolis, Minnesota, United States
Omaha, Nebraska, United States
Baltimore, Maryland, United States
Detroit, Michigan, United States
Hamilton, Ontario, Canada
Durham, North Carolina, United States
Lexington, Kentucky, United States
Iowa City, Iowa, United States
San Diego, California, United States
Columbus, Ohio, United States
Omaha, Nebraska, United States
Patients applied
Trial Officials
Frederick Korley, MD, PhD
Principal Investigator
University of Michigan
William Barsan, MD
Principal Investigator
University of Michigan
Gaylan Rockswold, MD, PhD
Principal Investigator
Hennepin Healthcare
Byron Gajewski, PhD
Principal Investigator
University of Kansas
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials